Assessing Legend Biotech: Insights From 15 Financial Analysts
Portfolio Pulse from Benzinga Insights
Legend Biotech (NASDAQ: LEGN) has been analyzed by 15 financial analysts, revealing a range of sentiments from bullish to somewhat bullish. The average 12-month price target is $80.67, with a high of $90.00 and a low of $60.00. Recent ratings show a slight decline in the average price target. The company's financial performance shows strong revenue growth but challenges in profitability and returns.
June 21, 2024 | 3:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Legend Biotech has received a range of bullish to somewhat bullish ratings from 15 analysts. The average 12-month price target is $80.67, with a high of $90.00 and a low of $60.00. The company's financial performance shows strong revenue growth but challenges in profitability and returns.
The majority of analysts have a bullish outlook on Legend Biotech, with an average price target of $80.67. The company's strong revenue growth is a positive indicator, although challenges in profitability and returns may temper expectations. Overall, the sentiment is likely to have a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100